Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Viral load news

Show

From To
Age difference in HIV infection matters – but it’s not always the younger person who is at risk

A European study of men who have sex with men (MSM) presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) shows that age

Published
19 March 2018
By
Gus Cairns
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason

Darunavir/ritonavir (DRV/r) is the most durable boosted protease inhibitor for antiretroviral therapy (ART)-experienced people, investigators from the EuroSIDA cohort report in HIV Medicine. People switching

Published
13 February 2018
By
Michael Carter
Faster action on adherence is needed after viral load becomes detectable, researchers warn global treatment programmes

Low-level HIV viral load, above the limit of detection, is an important warning signal for future treatment failure and World Health Organization guidelines on spotting treatment failure

Published
12 January 2018
By
Keith Alcorn
Baseline CD4 count biggest factor in long-term immune system improvements after starting HIV therapy

Pre-treatment CD4 cell count is the most important factor in immune recovery following the initiation of combination antiretroviral therapy (cART), according to the results of a large observational

Published
14 December 2017
By
Michael Carter
HIV-positive children in resource-limited settings can achieve good virological outcomes without routine viral load or CD4 cell count monitoring

HIV-positive children can achieve good virological outcomes without routine monitoring of CD4 cell count or viral load, investigators report in PLOS Medicine. The research was

Published
27 November 2017
By
Michael Carter
Schistosomiasis increases risk of infection with HIV, especially for women and is also associated with a higher HIV viral load

Infection with schistosome parasitic worms has an important role in HIV transmission, especially for women, and may accelerate HIV disease progression, according to research published in PLOS Neglected

Published
20 November 2017
By
Michael Carter
Virally suppressed people have “effectively no risk” of transmitting HIV, says US CDC: but how many are suppressed?

The US Centers for Disease Control and Prevention (CDC) used 27 September, National Gay Men’s HIV/AIDS Awareness Day, to announce that HIV diagnoses had fallen in white

Published
03 October 2017
By
Gus Cairns
Amsterdam PrEP failure patient had unusual course of HIV infection

At last February’s Conference on Retroviruses and Opportunistic Infections (CROI), Dutch clinicians presented a so-far unique case of a man who had apparently become infected

Published
02 October 2017
By
Gus Cairns
Single measures of viral load not effective for assessing HIV suppression status

The percentage of HIV-positive individuals with durable viral suppression may be overestimated when calculated by single measures of viral load, according to findings published in Annals of Internal Medicine.

Published
08 August 2017
From
Healio
Viral Rebound Unlikely for Many on ART

British investigators have determined that a substantial proportion of people with HIV who are taking antiretroviral therapy (ART) will not experience viral rebound during their lifetime.

Published
14 July 2017
From
Infectious Disease Special Edition
← First12345...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.